Compare CPAC & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPAC | IOVA |
|---|---|---|
| Founded | 1949 | 2007 |
| Country | Peru | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 905.9M | 881.3M |
| IPO Year | 2012 | N/A |
| Metric | CPAC | IOVA |
|---|---|---|
| Price | $10.63 | $2.33 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 12 |
| Target Price | $10.15 | ★ $10.45 |
| AVG Volume (30 Days) | 34.5K | ★ 12.5M |
| Earning Date | 02-13-2026 | 02-26-2026 |
| Dividend Yield | ★ 5.46% | N/A |
| EPS Growth | ★ 20.27 | N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $601,081,883.00 | $250,425,000.00 |
| Revenue This Year | $9.96 | $60.71 |
| Revenue Next Year | $1.70 | $59.52 |
| P/E Ratio | $14.09 | ★ N/A |
| Revenue Growth | 6.18 | ★ 175.62 |
| 52 Week Low | $5.10 | $1.64 |
| 52 Week High | $11.30 | $6.50 |
| Indicator | CPAC | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 62.78 | 45.76 |
| Support Level | $10.14 | $2.21 |
| Resistance Level | $10.80 | $2.80 |
| Average True Range (ATR) | 0.34 | 0.18 |
| MACD | -0.10 | -0.05 |
| Stochastic Oscillator | 43.16 | 20.74 |
Cementos Pacasmayo SAA is a Peruvian cement company that produces, distributes, and sells cement and cement-related materials, such as concrete blocks and ready-mix concrete. The company's products are used in construction. It also produces and sells quicklime for use in mining operations. The company sells its products mainly in the northern part of Peru. It owns three cement production and transportation facilities. Its flagship Pacasmayo facility is located in the northwest region of Peru, while its new cement plant in Piura and smaller Rioja facility are located in the northeast region of Peru.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.